


Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claims 1-3 CANCELED


4. (currently amended) A compound comprising the structure of formula I:
wherein:




- Ring A is optionally substituted with one to five substituents selected from
 - a) a C₁, C₂, C₃, C₄ or C₅ branched or straight-chain lower alkoxy, cycloalkoxy, heterocycloalkoxy, aryloxy, or lower alkanoyloxy; or
 - b) a halogen or trihaloalkyl;
 - Ring B comprises at least one structure denoted by R_a and R_b which represent an *ortho*-quinone moiety $-(C=O)-(C=O)-$, *ortho*-catechol $-(C-OH)-(C-OH)-$ or *ortho*-catechol prodrug moiety $-(C-O-Prodrug\ moiety)-(C-O-Prodrug\ moiety)-$; and the remaining carbons of Ring B are optionally substituted with one to five substituents selected from
 - a) a C₁, C₂, C₃, C₄ or C₅ branched or straight-chain lower alkoxy, cycloalkoxy, heterocycloalkoxy, aryloxy, or lower alkanoyloxy;
 - b) a halogen or trihaloalkyl;
 - c) a C₁, C₂, C₃, C₄ or C₅ branched or straight chain lower alkyl, allyl, allyloxy, vinyl, or vinyloxy; or
 - d) an OH, or a C₁, C₂, C₃, C₄ or C₅ primary, secondary, or tertiary alcohol;
 - e) nitro; and
 - Bridge X is an alkene $-(CR_9=CR_{10})-$, wherein R₉ and R₁₀ are alternatively H, alkyl, amino, amido, cyano, hydroxyl, or carboxyl;
- provided that said compound is not combretastatin A1 or a salt, ester, or prodrug thereof.

Claims 5 - 9 CANCELED

10. (currently amended) A compound comprising a quinone, quinone prodrug, or a pharmaceutically acceptable salt form thereof having one of the following general structures:



or



wherein:

a. R₁, R₅, R₆, and R₇ are H;

— R₂, R₃, R₄, R₈, R₆, R₇, and R₈ are the same or different and are selected from hydrogen and:

- i) a C₁, C₂, C₃, C₄ or C₅ branched or straight-chain lower alkoxy, cycloalkoxy, heterocycloalkoxy, aryloxy, or lower alkanoyloxy;
- ii) a halogen or trihaloalkyl;
- iii) a C₁, C₂, C₃, C₄ or C₅ branched or straight chain lower alkyl, allyl, allyloxy, vinyl, or vinyloxy; or
- iv) a C₁, C₂, C₃, C₄ or C₅ primary, secondary, or tertiary alcohol;

R₈ is selected from:

- i) a C₁, C₂, C₃, C₄ or C₅ branched or straight-chain lower alkoxy, cycloalkoxy, heterocycloalkoxy, aryloxy, or lower alkanoyloxy;

ii) a halogen or trihaloalkyl;

iii) a C₁, C₂, C₃, C₄ or C₅ branched or straight chain lower alkyl, allyl, allyloxy, vinyl, or vinyloxy;

iv) a C₁, C₂, C₃, C₄ or C₅ primary, secondary, or tertiary alcohol; or

v) nitro;

and the remaining R₄₁, R₄₂, R₄₃, R₄₄, R₄₅, R₄₆, R₄₇, or R₄₈ are H; and

b. X is an alkene (-CR₉=CR₁₀-), wherein R₉ and R₁₀ are alternatively H, alkyl, amino, amido, cyano, hydroxyl, or carboxyl

provided that said compound is not combretastatin A1 or a salt, ester, or prodrug thereof.

11. (canceled)

12. (previously presented) The compound of claim 10, wherein X is an ethylene group (-CH=CH-), and Rings A and B are in a cis (Z) isomeric configuration.

13. (original) The compound of claim 12, wherein R₂, R₃ and R₄ are methoxy.


14. (canceled)

15. (currently amended) The compound of claim 44 10, wherein R₈ is ~~OH or~~ -O-CH₂-CH=CH₂.

16. (original) The compound of claim 4, wherein said catechol is a biooxidative agent which is oxidatively activated *in vivo* to form a quinone capable of participating in a redox cycling reaction to form one or more Reactive Oxygen Species ("ROS").

Claims 17-33 CANCELED

34. (currently amended) A composition of the following formula (V):



wherein

a. Z is an ethylene (-CH=CH-) bridge in the cis (Z) isomeric configuration;

b. R₁ and R₂ are OH or a prodrug form thereof;

c. R₃ is

i) a C₁, C₂, C₃, C₄ or C₅ branched or straight-chain lower alkoxy, cycloalkoxy, heterocycloalkoxy, aryloxy, or lower alkanoyloxy;

ii) a halogen or trihaloalkyl;

iii) a C₁, C₂, C₃, C₄ or C₅ branched or straight chain lower alkyl, allyl, allyloxy, vinyl, or vinyloxy;

iv) an OH, or a C₁, C₂, C₃, C₄ or C₅ primary, secondary, or tertiary alcohol; or

v) oxo, lower alkanoyl, thio, sulfonyl, sulfonamide, nitro, nitrosyl, cyano, carboxy, carbamyl, aryl, or heterocycle;

d. R₄, R₅, and R₆ are hydrogen,

e. R₃, R₄, R₅, R₆, R₇, and R₈ are the same or different and selected from hydrogen and

i) a C₁, C₂, C₃, C₄ or C₅ branched or straight-chain lower alkoxy, cycloalkoxy, heterocycloalkoxy, aryloxy, or lower alkanoyloxy;

ii) a halogen or trihaloalkyl;

iii) a C₁, C₂, C₃, C₄ or C₅ branched or straight chain lower alkyl, allyl, allyloxy, vinyl, or vinyloxy; or

iv) a C₁, C₂, C₃, C₄ or C₅ primary, secondary, or tertiary alcohol;

v) nitro; and

the remaining R₃, R₄, R₅, R₆, R₇, R₈ and R₉ are hydrogen,

provided that said compound is not combretastatin A1 or prodrug thereof.

35. (currently amended) The composition of claim 34, wherein ~~at least three of~~ R_6 , R_7 , and R_8 ~~and~~ R_9 are not hydrogen.

36. (original) The composition of claim 35, wherein R_6 , R_7 and R_8 are the same.

37. (original) The composition of claim 36, wherein R_6 , R_7 and R_8 are methoxy.

38. (canceled)

39. (currently amended) The composition of claim ~~38~~ 37, wherein R_3 is $-\text{CH}_3$, $-\text{CH}_2\text{CH}_3$, $-\text{OCH}_2\text{CH}_3$, $-\text{F}$, $-\text{Br}$, $-\text{CF}_3$, $-\text{CBr}_3$, ~~$-\text{OH}$~~ , $-\text{O}-\text{CH}_2-\text{CH}=\text{CH}_2$, $-\text{CH}_2-\text{CH}=\text{CH}_2$, $-\text{NO}_2$, -cyano, or -carboxy.

40. (currently amended) The composition of claim ~~39~~ 36, wherein R_6 , R_7 , and R_8 are F.

41. (canceled)

42. (currently amended) The composition of claim ~~44~~ 40, wherein R_3 is $-\text{CH}_3$, $-\text{CH}_2\text{CH}_3$, $-\text{OCH}_2\text{CH}_3$, $-\text{F}$, $-\text{Br}$, $-\text{CF}_3$, $-\text{CBr}_3$, ~~$-\text{OH}$~~ , $-\text{O}-\text{CH}_2-\text{CH}=\text{CH}_2$, $-\text{CH}_2-\text{CH}=\text{CH}_2$, $-\text{NO}_2$, -cyano, -carboxy, or -benzyl.

Claims 43-56 CANCELED

57. (currently amended) A composition selected from the group consisting of

~~6-[(Z)-2-(3,4,5-trimethoxyphenyl)vinyl]-1,2-dihydroxybenzene,~~
 3-Ethyl-6-[(Z)-2-(3,4,5-trimethoxyphenyl)vinyl]-1,2-dihydroxybenzene,
 3-Methyl-6-[(Z)-2-(3,4,5-trimethoxyphenyl)vinyl]-1,2-dihydroxybenzene,
 4-Bromo-6-[(Z)-2-(3,4,5-trimethoxyphenyl)vinyl]-1,2-dihydroxybenzene,
 4-Phenyl-6-[(Z)-2-(3,4,5-trimethoxyphenyl)vinyl]-1,2-dihydroxybenzene,
 3-Allyl-6-[(Z)-2-(3,4,5-trimethoxyphenyl)vinyl]-1,2-dihydroxybenzene,
 4-Fluoro-6-[(Z)-2-(3,4,5-trimethoxyphenyl)vinyl]-1,2-dihydroxybenzene,
 2,3,4-Trihydroxy-6-[(Z)-2-(3,4,5-trimethoxyphenyl)vinyl]-benzene,
 2,3-Dihydroxy-4-ethoxy-6-[(Z)-2-(3,4,5-trimethoxyphenyl)vinyl]-benzene,
 2,3-Dihydroxy-4-allyloxy-6-[(Z)-2-(3,4,5-trimethoxyphenyl)vinyl]-benzene,
 4-Nitro-6-[(Z)-2-(3,4,5-trimethoxyphenyl)vinyl]-2,3-dihydroxybenzene,

2',3'dihydroxy -3,5 dichloro4,4'-dimethoxy-(Z)-stilbene,
2',3' dihydroxy-4'-methoxy-3,4,5-trifluoro-(Z)-stilbene,
2,3-Dihydroxy-4-methoxy-[(Z)-2-(3,4,5-trimethoxyphenyl) Beta-lactam]-benzene,
2',3' diphosphate-3,4,5-trimethoxy-(Z)-stilbene, tetrasodium salt;
3',4' diphosphate-3,4,5-trimethoxy-(Z)-stilbene, tetrasodium salt;
and combinations thereof.

58. (previously presented) The compound of claim 4, wherein X is an ethylene group
(-CH=CH-), and Rings A and B are in a cis (Z) isomeric configuration